Berlin, Germany, and Manchester, UK, January 14, 2008Epigenomics AG (Frankfurt, Prime Standard: ECX) and DxS Ltd.(Manchester, UK) today announced that they have entered into astrategic cross-licensing agreement. Under the terms of theagreement, Epigenomics obtains worldwide non-exclusive rights to DxS’proprietary Scorpions® technology for R&D use and research kits, aswell as an Option to expand the license to the in vitro diagnostics(IVD) field. Epigenomics intends to use this technology both incertain research kits as well as potentially in its cancer specialtydiagnostics products.
